Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Narrative)

v3.22.1
Commitments and Contingencies (Details Narrative)
 3 Months Ended
Feb. 07, 2022
USD ($)
Nov. 19, 2021
ft²
Mar. 26, 2021
USD ($)
Oct. 05, 2020
Mar. 31, 2022
USD ($)
Loss Contingencies [Line Items]          
Litigation settlement expense $ 425,000        
Project fees         $ 2,100,000
Recorded expenses         1,100,000
Other commitments, description       On October 5, 2020, GT Biopharma entered into a Master Services Agreement with a third-party product manufacturer to perform biologic development and manufacturing services on behalf of the Company. Associated with this, the Company has subsequently signed five Statements of Work for the research and development of products for use in clinical trials. At March 31 2022, the Company’s commitments in relation to these Statements of Work and any related Change Orders totaled approximately $13.0 million, of which $8.4 million was incurred at that date and an additional $4.6 million is in process during fiscal year 2022  
Rent expense         29,000
Aimmune Therapeutics Inc [Member]          
Loss Contingencies [Line Items]          
Area of land | ft²   4,500      
Commencement date   commencement date of January 1, 2022 and maturing on June 30, 2024      
Master Services Agreement [Member] | Cytovance Biologics, Inc. [Member]          
Loss Contingencies [Line Items]          
Commitment amount for services, total         13,000,000.0
Commitment cost incurred         8,400,000
Compensation cost expected to be incurred in future         4,600,000
2016 Patent License Agreement [Member]          
Loss Contingencies [Line Items]          
Received upfront payment         200,000
Annual maintanance fee         $ 100,000
[custom:RoyaltyFeePercentage]         0.04
Performance milestone payments         $ 3,100,000
Sales milestone payments         1,000,000.0
Gross sales         250,000,000
Sales revenue         5,000,000.0
Cummulative gross sales         500,000,000
2016 Patent License Agreement [Member] | Minimum [Member]          
Loss Contingencies [Line Items]          
Annual royalty payments         250,000
2016 Patent License Agreement [Member] | Maximum [Member]          
Loss Contingencies [Line Items]          
Annual royalty payments         5,000,000.0
2021 Patent License Agreement [Member]          
Loss Contingencies [Line Items]          
Annual royalty payments         250,000
Performance milestone payments         3,100,000
Sales milestone payments         1,000,000.0
Gross sales         250,000,000
Sales revenue         5,000,000.0
Cummulative gross sales         500,000,000
Upfront license fee     $ 20,000    
License maintenance fee, receivable         5,000
Maintanance fee         $ 2,000,000.0
2021 Patent License Agreement [Member] | Minimum [Member]          
Loss Contingencies [Line Items]          
Net sales percentage         0.025
2021 Patent License Agreement [Member] | Maximum [Member]          
Loss Contingencies [Line Items]          
Net sales percentage         0.05